This site is intended for healthcare professionals residing in Canada.

Visit Pfizer AcademySearch

Menu

Close

Sign InLog Out
  • EN
ProductsTherapy AreasExplore ContentExplore
ContentGo to Explore ContentEventsMaterialsVideosPatient SupportContact
EN - EnglishSelect a languageLanguagesEN - EnglishFR - Français

Menu

Close

Home

Recommendations

SOGC Recommendations

NACI Recommendations

CIQ Recommendations

About RSV

About RSV

Infants at Risk

Individuals ≥ 60 Years of Age

About ABRYSVO

Reconstitution and Storage

Dosing and Administration

Mechanism of Action

Efficacy and Safety Profiles

Clinical Trials

MATISSE Study Design

MATISSE Data

MATISSE Safety Profile

RENOIR Study Design

RENOIR Data

RENOIR Safety Profile

More

Coverage Information

Patient Profiles

FAQ

Resources

Product MonographSafety Information
Pfizer Respiratory Vaccine Portfolio
About respiratory syncytial virusA very common, highly contagious virus that causes infections of the respiratory tract1

RSV represents a large burden of disease in Canada and is estimated to annually cause 3.4 million hospitalizations and 100,000 deaths globally.2

In severe cases, RSV can lead to:1,3*†

*ABRYSVO is not indicated to prevent:

  • Severe LRTD caused by RSV in individuals 60 years of age and older.
  • RSV-associated hospitalization/death.
ABRYSVO did not have a statistically significant result in the hospitalization endpoint in the maternal/infant indication.

†Please refer to the RENOIR and MATISSE study for the definition of severe LRTD.Who’s at high risk for severe RSV infection? Infants Learn more Loading Individuals ≥ 60 years of age Learn more LoadingRSV disease burden is the greatest in the first 2 years of life and in older adults.2Most RSV cases occur December through March.3

RSV: respiratory syncytial virus; LRTD: lower respiratory tract disease; SOGC: Society of Obstetricians and Gynaecologists of Canada; NACI: National Advisory Committee on Immunization; CIQ: Comité sur l’immunisation du Québec

About RSVRecommendations

Learn more about SOGC, NACI, and CIQ recommendations.

SOGC Recommendations

NACI Recommendations

CIQ Recommendations

 About ABRYSVO

Find information about ABRYSVO.

Reconstitution and Storage

Dosing and Administration

Mechanism of Action

References:National Collaborating Centre for Infectious Diseases. Respiratory syncytial virus (RSV) 2022 update. Accessed August 10, 2023. https://nccid.ca/debrief/respiratory-syncytial-virus-rsv/.Killikelly A et al. Overview of the respiratory syncytial virus vaccine candidate pipeline in Canada. Can Commun Dis Rep. 2020;46(4):56–61.Government of Canada. Respiratory syncytial virus (RSV): for health professionals. Accessed September 18, 2024. https://www.canada.ca/en/public-health/services/diseases/respiratory-syncytial-virus-rsv/health-professionals.html.
PP-A1G-CAN-0117-EN

To report an adverse event, please call 1-866-723-7111

PfizerPro AccountPfizerPro Account

To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.

Sign in or RegisterSign inRegisterAccountSign Out

© Pfizer Canada ULC 2024. All rights reserved. The information is intended only for healthcare professionals resident in Canada. ®Pfizer Inc., used under license.

PP-UNP-CAN-0145-EN
You are now leaving Pfizerpro.ca website
Links to other sites are provided as a convenience to the viewer, and should not be taken as an endorsement of the sites or an association with their owners. Pfizer Canada accepts no responsibility for the content of linked sites.
You are now leaving the PfizerPro Portal.
You are about to view resources made available by Pfizer Academy. 
These resources include learning programs and upcoming events. By selecting Go to link below, you acknowledge and certify that you are a Canadian Healthcare Professional.
PP-UNP-CAN-0013 EN
Are you a resident of Quebec?